ResearcherNational Cancer InstituteNo recent work listed

Ji Luo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5063-1626; OpenAlex author ID A5044758224. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2021: 2 papers

Papers 2

Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1. Co-author DOI 10.1038/s41388-021-02040-9 ↗
KRAS mutation in pancreatic cancer. Co-author DOI 10.1053/j.seminoncol.2021.02.003 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yan Han · 1 shared paper, 2021 · strength 0.11
- Paper Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1. DOI 10.1038/s41388-021-02040-9 ↗
Yi Miao · 1 shared paper, 2021 · strength 0.11
- Paper Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1. DOI 10.1038/s41388-021-02040-9 ↗
Wanglong Qiu · 1 shared paper, 2021 · strength 0.11
- Paper Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1. DOI 10.1038/s41388-021-02040-9 ↗
Haoqiang Ying · 1 shared paper, 2021 · strength 0.11
- Paper Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1. DOI 10.1038/s41388-021-02040-9 ↗
Gloria Huei-Ting Su · 1 shared paper, 2021 · strength 0.11
- Paper Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1. DOI 10.1038/s41388-021-02040-9 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.